Valtrex 500mg 42 tablets — Made in Spain — Free Delivery

Product description 

Valtrex™ tablets are used for the following indications:

• treatment of herpes zoster (Herpes zoster);
• treatment of infections of the skin and mucous membranes caused by the herpes simplex virus, including primary and recurrent genital herpes;
• treatment of labial herpes (labial fever);
• preventive treatment (suppression) of recurrent infections of the skin and mucous membranes caused by the herpes simplex virus, including genital herpes;
• reducing the risk of transmission of the genital herpes virus to a healthy partner when using the preparation "Valtrex™" as a suppressive therapy in combination with the observance of the rules of safe sex;
• prevention of cytomegalovirus infection and disease after organ transplantation.

Compound

The active substance is valaciclovir (one tablet contains 500 mg of valaciclovir (as valaciclovir hydrochloride)).

Excipients: microcrystalline cellulose, crospovidone, povidone, magnesium stearate, anhydrous colloidal silicon dioxide, carnauba wax, white dye concentrate (YS-1-18043): hypromellose, titanium dioxide (E 171), polyethylene glycol 400, polysorbate 80.

Contraindications

"Valtrex™" is contraindicated in patients with hypersensitivity to valacyclovir, acyclovir or any component of the preparation.

Mode of application

Herpes zoster treatment

For adults, prescribe 1000 mg (two tablets) 3 times a day for 7 days.

Treatment of infections caused by the herpes simplex virus

Patients with normal immunity (adults): 500 mg (one tablet) 2 times a day.

For relapses, treatment should last 3 or 5 days. In the primary course, which may be more severe, treatment should be continued from 5 to 10 days. Treatment should begin as soon as possible. For recurrences of forms of infections caused by the herpes simplex virus, it would be ideal to use the preparation in the prodromal period or immediately after the onset of the first symptoms. The preparation "Valtrex ™" can prevent the development of lesions in recurrent infections caused by the herpes simplex virus, provided that treatment is started immediately after the first symptoms of the disease appear.

Alternatively, for the treatment of labial herpes (labial fever), an effective dose of Valtrex™ is 2000 mg (4 tablets) 2 times a day for one day. The second dose should be administered approximately 12 hours (not earlier than 6 hours) after the first dose. With this dosing regimen, the duration of treatment should not exceed one day, since it has been proven that prolonged use does not increase the clinical efficacy of treatment. Treatment should begin at the first early symptoms of herpes labialis (tingling sensation, itching or burning in the lips).

Preventive treatment (suppression) of recurrent infections caused by herpes simplex virus

Recommended dosage:

• patients with normal immunity (adults) to prescribe 500 mg (one tablet) 1 time per day;
• patients with immunodeficiency (adults) to prescribe a dose of 500 mg (one tablet) 2 times a day.

Reducing the transmission of genital herpes virus

For heterosexual adults with normal immunity who have 9 or fewer exacerbations per year, Valtrex™ should be administered to an infected partner at a dose of 500 mg 1 time per day.

There are no data on the reduction of transmission of the genital herpes virus in other patient populations.

Prevention of cytomegalovirus infection and disease after organ transplantation

Adults and children over the age of 12: Valtrex™ is prescribed at a dose of 2000 mg (4 tablets) 4 times a day as soon as possible after transplantation. In renal insufficiency, the doses are reduced. The duration of treatment is usually 90 days, but may be extended for high-risk patients.

Application features

pregnant

"Valtrex™" for the treatment of pregnant women can be used only when the potential benefit from the treatment of the mother outweighs the possible risk to the fetus.

Prescribe this preparation to women during breastfeeding with caution, only in cases of clinical necessity.

Clinical studies on the effect of Valtrex™ on human fertility have not been conducted, however, after 6 months of daily use of acyclovir at a dose of 400 mg to 1 g, no changes in the number, morphology and motility of spermatozoa were observed.

Children

The preparation is used in children over 12 years of age for the prevention of cytomegalovirus infection and disease after organ transplantation.

Drivers

There are no data from clinical studies on this issue, the pharmacology of valaciclovir does not give reason to expect any negative effect. However, when assessing the patient's ability to drive a car and other mechanisms, one should take into account his clinical condition and the side effect profile of the Valtrex ™ preparation.

Overdose

Symptoms

With an overdose of valaciclovir, the development of acute renal failure and neurological symptoms, including confusion, hallucinations, agitation, mental decline and coma, have been reported. Nausea and vomiting are possible. To prevent unintentional overdose, care should be taken when using. Many cases of overdose have been associated with the use of the preparation for the treatment of patients with renal insufficiency and elderly patients who have not been dose reduced accordingly.

Treatment

Patients should be under close medical supervision to detect signs of toxicity. Hemodialysis significantly accelerates the elimination of acyclovir from the blood and therefore can be considered the best treatment option in case of symptomatic overdose.

Side effects

The most common adverse reactions reported in clinical studies were headache and nausea. More serious adverse reactions have included reports of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome, acute renal failure, and neurological impairment.

Storage conditions

Store in the original packaging at a temperature not exceeding 30°C, out of the reach of children.

Shelf life - 3 years.